WHO launches first clinical trial of antiviral to prevent Bundibugyo strain of Ebola in DR Congo
The World Health Organization has announced the launch of the first clinical trial designed to test whether an antiviral drug can prevent Ebola infection in people who have been exposed to the Bundibugyo strain of the virus in the Democratic Republic of Congo. The trial, which began on Tuesday, comes as the ongoing outbreak continues to outpace response efforts and spread beyond previously identified chains of transmission.
Targeting the Bundibugyo strain
The Bundibugyo strain is one of several known species of the Ebola virus and has been responsible for multiple outbreaks in central Africa over the past two decades. Unlike the more widely studied Zaire strain, Bundibugyo has historically received less attention from researchers, leaving health authorities with a narrower set of medical tools when cases emerge. The new trial represents the first effort specifically aimed at evaluating an antiviral for preventive use against this particular strain.
Why post-exposure prevention matters
In Ebola outbreaks, post-exposure prophylaxis is considered a critical component of outbreak control. Health workers, family members of confirmed patients, and others who come into contact with infected individuals are at heightened risk, and preventive treatment could help break transmission chains before they widen. The current trial is expected to focus on individuals who have been identified through contact-tracing efforts as having had recent exposure to a confirmed case.
A response under pressure
Health authorities in DR Congo have struggled to contain the present outbreak, with transmission reportedly moving beyond the networks initially identified by surveillance teams. Such dynamics complicate contact tracing, vaccination campaigns, and infection prevention measures, and have raised concerns among regional health bodies about the risk of the outbreak extending further. The launch of the antiviral trial reflects an effort to expand the limited medical arsenal available to responders on the ground.
Bigger picture for Ebola response
The Democratic Republic of Congo has long served as the epicentre of Ebola research and response, having faced more outbreaks than any other country. Advances in vaccines and therapeutics over recent years have transformed the outlook for patients infected with the Zaire strain, but researchers have repeatedly stressed that similar progress is needed for other species of the virus. The new trial is being watched as a potential step toward closing that gap and strengthening global preparedness against a pathogen that remains a persistent regional threat.
Source: FRANCE 24 — read the original report.
